Halozyme Therapeutics Valuation
Is HALO * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of HALO * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: HALO * (MX$680) is trading below our estimate of fair value (MX$2060.12)
Significantly Below Fair Value: HALO * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HALO *?
Other financial metrics that can be useful for relative valuation.
What is HALO *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$5.20b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 8x |
Enterprise Value/EBITDA | 15.8x |
PEG Ratio | 0.8x |
Price to Earnings Ratio vs Peers
How does HALO *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 34.7x | ||
002252 Shanghai RAAS Blood Products | 26.2x | 24.6% | CN¥47.7b |
BIOCON Biocon | 29.7x | 8.7% | ₹356.5b |
300896 Imeik Technology DevelopmentLtd | 32.8x | 25.2% | CN¥64.6b |
688363 Bloomage BioTechnology | 50x | 26.8% | CN¥29.6b |
HALO * Halozyme Therapeutics | 20.5x | 24.1% | Mex$5.2b |
Price-To-Earnings vs Peers: HALO * is good value based on its Price-To-Earnings Ratio (20.5x) compared to the peer average (36.4x).
Price to Earnings Ratio vs Industry
How does HALO *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Earnings vs Industry: HALO * is good value based on its Price-To-Earnings Ratio (20.5x) compared to the Global Biotechs industry average (34.5x).
Price to Earnings Ratio vs Fair Ratio
What is HALO *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 20.5x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate HALO *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.